Core Insights - COEPTIS, Inc. has formed a majority-owned subsidiary, GEAR Therapeutics, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for various cancers and therapeutic modalities [1] - The GEAR™ Cell Therapy Platform offers a first-in-class approach to modifying immune cells, aiming to enhance remission rates in patients with hematologic malignancies and other cancers [1] - GEAR-NK cells are designed to be co-administered with targeted monoclonal antibodies, potentially improving treatment outcomes by avoiding neutralization by mAb therapy [2][3] Company Developments - COEPTIS has successfully licensed exclusive worldwide development and commercialization rights to the GEAR platform from VyGen-Bio, Inc., expanding its ownership and capabilities in the biotechnology sector [1][4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a commitment to improving patient outcomes through advanced research [5][6] - COEPTIS has established a Technology Division to enhance operational capabilities, incorporating AI-powered marketing software and robotic process automation tools [7] Market Potential - The GEAR technology is expected to address significant therapeutic needs in the market, providing a cost-effective option for patients requiring advanced cancer therapies [4] - The GEAR platform also has the potential to modify hematopoietic stem cells in combination with mAbs, which could improve bone marrow transplant outcomes for hematological malignancies [2]

Core Insights - COEPTIS, Inc. has announced a strategic partnership with Arketyp Valu to integrate advanced digital marketing solutions into the ValuSocial platform, leveraging Verus Coin and blockchain technology [1][2][3] - The ValuSocial platform aims to revolutionize digital marketing by providing a fully immersive environment for targeted campaigns, enhancing user engagement through blockchain security and scalability [2][3] Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative cell therapy platforms for various diseases, aiming to improve patient outcomes through advanced research and development [4][5] - The company has established a Technology Division to enhance operational capabilities, incorporating AI-powered marketing software and robotic process automation tools from NexGenAI Solutions Group [6] Partnership Details - The collaboration between COEPTIS and Arketyp Valu is set to merge digital marketing innovation with the Verus network's reliable framework, creating a decentralized digital ecosystem [3] - The partnership emphasizes the commitment to drive innovation and redefine digital marketing capabilities, with the ValuSocial platform built on the secure foundations of the Verus Project [3][8] Technology and Market Position - Verus Coin, part of the Verus project, focuses on privacy, security, and scalability, aiming to create a decentralized ecosystem that empowers users and supports application development [7][8] - NexGenAI Affiliates Network is designed to optimize affiliate marketing efforts through automation and advanced analytics, enhancing revenue generation for businesses [9]

Core Insights - COEPTIS, Inc. has announced a partnership with MarketLeverage to integrate AI technology into affiliate marketing, aiming to enhance performance-based strategies [1][2][3] - The collaboration will leverage MarketLeverage's extensive network of 5,500 advertisers and 55,000 publishers to drive traffic and improve marketing efficiency [2][3] - The partnership is expected to transform digital marketing by providing affiliates and brands with advanced automation and data-driven insights [3][4] Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative cell therapy platforms and advanced technologies [7][9] - The company has established a Technology Division that includes AI-powered marketing software and robotic process automation tools [9] - COEPTIS aims to improve patient outcomes through cutting-edge research and development efforts in the biopharmaceutical sector [7][8] Market Trends - The artificial intelligence in marketing market is projected to grow from $27.83 billion in 2024 to $35.54 billion in 2025, reflecting a compound annual growth rate (CAGR) of 27.7% [5] - By 2029, the market size is expected to reach $106.54 billion, with a CAGR of 31.6%, indicating significant growth potential in the AI-driven marketing sector [5]

Core Viewpoint - COEPTIS, Inc. has announced a strategic partnership with MarketLeverage to enhance affiliate marketing through AI technology integration, aiming to improve marketing efficiency and performance-based strategies [1][2][3]. Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative biotechnology solutions, including cell therapy platforms for various diseases [7][8]. - The company has established a Technology Division that includes AI-powered marketing software and robotic process automation tools to optimize business processes [9]. Partnership Details - The collaboration between COEPTIS' NexGenAI Affiliates Network and MarketLeverage will leverage advanced automation and data-driven insights to empower affiliates, brands, and marketers [2][4]. - MarketLeverage has a vast network, currently working with 5,500 advertisers and 55,000 publishers, which will enhance the reach and effectiveness of the partnership [2][10]. Market Insights - The artificial intelligence in marketing market is projected to grow from $27.83 billion in 2024 to $35.54 billion in 2025, with a compound annual growth rate (CAGR) of 27.7% [5]. - The market is expected to reach $106.54 billion by 2029, with a CAGR of 31.6%, indicating significant growth potential in the AI-driven marketing sector [5]. Technological Advancements - NexGenAI Affiliates Network provides AI-driven tools for campaign management, predictive analytics, and automated outreach, enhancing the capabilities of affiliates and advertisers [4][11]. - The partnership aims to create a new frontier in performance marketing by combining MarketLeverage's extensive network with NexGenAI's automated tools [3][4].

Core Perspective - COEPTIS, Inc. has launched COEP Venture Group, an investment arm focused on funding and accelerating technology startups in AI, Robotic Process Automation (RPA), and AI Agents [1][2][3] Investment Strategy - COEP Venture Group aims to identify and support high-potential startups that are shaping the future of automation and intelligent systems by providing capital, mentorship, and access to industry networks [2][3] - The investment focus includes advanced machine learning models, AI-driven enterprise solutions, RPA, AI agents, and other emerging technologies such as blockchain and data analytics [8] Leadership and Expertise - Michael Woloshin, a seasoned entrepreneur with extensive experience in technology and marketing automation, will lead COEP Venture Group, leveraging his background to foster innovation and expand market opportunities for emerging tech companies [5] Strategic Initiatives - COEP Venture Group will utilize NexGenAI Solutions Group to provide marketing services to its portfolio companies, ensuring they receive not only funding but also strategic exposure and market positioning [4]

Core Insights - COEPTIS, Inc. successfully closed an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million, indicating strong investor confidence in the company's innovative therapeutic solutions and technology-driven growth [1][2][3] Financing Details - The financing round was led by CJC Investment Trust, controlled by board member Christopher Calise, who increased their initial investment [2] - The Series A Preferred shares are convertible into common stock at a price of $8.00 per share, with investors receiving a 15% equity interest in newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. [2] Use of Proceeds - The funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes, alongside enhancing operational capabilities through AI-driven tools from the NexGenAI Affiliates Network platform [3][4] - The additional capital will accelerate the integration of advanced AI solutions and automation capabilities, improving research processes and overall operational efficiency [3] Company Strategy - COEPTIS aims to drive innovation in technology and AI while fostering a culture of responsible innovation to create a self-sustaining business model for long-term success and profitability [4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a therapeutic portfolio that includes assets licensed from Deverra Therapeutics [5][6] Technology Division - A newly established Technology Division will enhance operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [6]

Core Insights - Coeptis Therapeutics Holdings, Inc. has rebranded to COEPTIS, indicating a strategic shift to expand beyond biopharmaceuticals into technology-driven sectors [1][3] - The establishment of a new Technology Division aims to enhance operational capabilities and maximize shareholder value, highlighted by the acquisition of the NexGenAI Affiliates Network platform [1][6] - The integration of NexGenAI's tools will empower COEPTIS to address marketing challenges with AI-driven precision and efficiency, focusing on automation and workflow optimization [2][6] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company dedicated to developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [5] - COEPTIS is committed to advancing treatment paradigms and improving patient outcomes through cutting-edge research and development efforts [4][5] Technology Division - The newly established Technology Division focuses on enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation [6] - This division aims to optimize business processes and improve overall efficiency, positioning COEPTIS as a self-sustaining entity for long-term growth and profitability [3][6]

Core Insights - Coeptis Therapeutics is expanding its technological initiatives by integrating artificial intelligence and blockchain solutions to enhance operational efficiency and strategic growth [1][2][3] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company operates through subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. [4] Technological Advancements - The successful launch of the Technology Division has introduced transformative AI capabilities, significantly improving operational efficiency and customer engagement [2][6] - The Technology Division includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [6] Strategic Vision - The integration of blockchain technology into the Technology Division reflects Coeptis's commitment to adapting to emerging trends and leveraging new market opportunities for enhanced value creation [3] - The company aims to remain at the forefront of technological developments while exploring synergies that benefit customers and shareholders [3]

Core Insights - Coeptis Therapeutics has secured five new clients with a total contract value of $1.7 million, indicating strong market interest in its NexGenAI Affiliates Network platform [1][2] - The company anticipates a revenue stream of $450,000 from Managed Services Agreements valued at $1.25 million, highlighting the immediate market opportunity for its AI-driven marketing solutions [2] - The CEO of Coeptis expressed optimism about the early uptake of the NexGenAI platform, emphasizing its potential to enhance customer engagement and marketing strategies [3][5] Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [5] - The company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR T technology licensed from the University of Pittsburgh [5] Technology and Innovation - The NexGenAI Affiliates Network is designed to revolutionize marketing and business operations through AI-driven marketing software, robotic process automation, and data analytics [7] - Upcoming features of the NexGenAI platform include an AI Dialer Service, AI SMS Service, and advanced RPA Assistance, aimed at enhancing communication and operational efficiency [8] Market Trends - The integration of AI in marketing is transforming the industry by enabling businesses to personalize campaigns, optimize in real-time, and gain insights into consumer behavior [4] - As AI technology evolves, it is expected to play a crucial role in shaping various sectors and driving advancements in business practices [4]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. will implement a 1-for-20 reverse stock split to comply with Nasdaq Capital Market listing requirements, following approval from its board and stockholders [1][4][5] Group 1: Reverse Stock Split Details - The reverse stock split will convert every 20 shares of the Company's common stock into one share, with no fractional shares issued; any resulting fractions will be rounded up to the next whole number [3] - The effective date for the reverse stock split is December 31, 2024, marking the first day of trading on a post-split basis [2][3] Group 2: Purpose and Approval - The reverse stock split aims to help the Company meet the minimum bid price requirement of $1.00 per share as mandated by Nasdaq rules [4] - The reverse split was approved at the Company's Annual Stockholder's Meeting on December 18, 2024, after which the board established the split ratio [5] Group 3: Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [7] - The Company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR technology licensed from the University of Pittsburgh [7]